A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

CONCORDE is a multi-institution, multi-arm, Phase IB study that will determine the recommended phase II dose (RP2D) and safety profiles of different DNA damage repair inhibitors (DDRis) when given in an open label fashion in combination with fixed dose curative intent radiotherapy (RT) in patients with stage IIB/IIIA/IIIB NSCLC, followed by up to 12 months of consolidation durvalumab immunotherapy in selected study arms. The RP2D will be evaluated by incorporating the number of observed dose limiting toxicities (DLTs) into a time to event continuous reassessment method (TiTE- CRM) model within

Trial Details

NCT ID
NCT04550104
Phase
PHASE1
Sponsor
University of Leeds
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Radiotherapy
  • Olaparib Oral Tablet [Lynparza]
  • AZD1390
  • Ceralasertib
  • AZD5305
  • Durvalumab
Locations (sample)
  • Belfast, United Kingdom|54.59682,-5.92541
  • Birmingham, United Kingdom|52.48142,-1.89983
  • Cambridge, United Kingdom|52.2,0.11667
  • Cardiff, United Kingdom|51.48,-3.18
  • Chelsea, United Kingdom|51.48755,-0.16936

Key Eligibility Criteria

  • Histologically or cytologically confirmed NSCLC (patients where the local MDT agree the diagnosis is NSCLC after review of the available pathology …
  • Not suitable for concurrent chemoradiotherapy/surgery due to tumour or patient factors
  • Stage IIB and III (TNM 8th Edition).
  • Planned to receive RT at curative intent doses (i.e., 60Gy) as part of treatment plan (either with or without induction chemotherapy).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →